Skip to main content

and
  1. Article

    Open Access

    Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antige...

    Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano in Nature Communications (2024)

  2. Article

    Open Access

    The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

    Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor e...

    Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén in Nature Communications (2021)

  3. Article

    Open Access

    TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

    The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In rece...

    Ylva Naeser, Hildur Helgadottir, Yvonne Brandberg, Johan Hansson in BMC Cancer (2020)

  4. Article

    Open Access

    Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

    While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic ...

    Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro in BMC Cancer (2019)

  5. No Access

    Article

    Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations

    The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationship between germline CDKN2A mutations and PC risk is uncertain, suggesting the existence of non-CDKN2A factors. O...

    **aohong R. Yang, Melissa Rotunno, Yanzi **ao, Christian Ingvar in Human Genetics (2016)

  6. Article

    Open Access

    Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan

    The neuron-glial antigen 2 (NG2) proteoglycan promotes pericyte recruitment and mediates pericyte interaction with endothelial cells. In the absence of NG2, blood vessel development is negatively impacted in s...

    Krissa Gibby, Weon-Kyoo You, Kuniko Kadoya, Hildur Helgadottir in Breast Cancer Research (2012)

  7. No Access

    Article

    The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma

    We have previously demonstrated an association of the human leukocyte antigen (HLA), HLA-A2 allele with ovarian and prostate cancer mortality as well as a segregation of the ancestral HLA haplotype (AHH) 62.1 ...

    Hildur Helgadottir, Emilia Andersson, Lisa Villabona in Cancer Immunology, Immunotherapy (2009)